Menu

About SRSE

Status epilepticus (SE) is an acute medical emergency of persistent, unremitting seizure lasting greater than five minutes. Patients with status epilepticus are considered super-refractory when they have failed to be weaned from third-line agents.

These patients require third-line agents to maintain seizure control. There are currently no FDA-approved treatments.

SRSE is a rare, life-threatening condition. There are 150,000 cases of status epilepticus annually in the US1, with approximately 25,000 of those cases progressing to SRSE.1-3

  • 1 DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. J Clin Neuro 1995; 12(4): 316-325.
  • 2 Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Epilepsia 2002; 43(2): 146-153.
  • 3 Novy J, Logroscino G, Rossetti AO. Epilepsia 2010; 51(2): 251-256.

Learn more about SRSE

Please fill out the following form to get more information.

Submitting…

Please submit your other inquiries here.

Note: You must be a health care professional (HCP) to fill out this form. By clicking submit, you are confirming you are a health care professional. Please do not include any patient-identifying information.

Specify Your Inquiry (A selection is required.)

Please fill out this form if you have a potential patient for the Phase 3 SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus (STATUS) Trial.

Note: You must be a health care professional (HCP) to fill out this form. By clicking submit, you are confirming you are a health care professional. Please do not include any patient-identifying information.

Please fill out this form if you are interested becoming a site or investigator for the Phase 3 SAGE-547 Treatment as Adjunctive Therapy Utilized in Status Epilepticus (STATUS) Trial.

Note: You must be a health care professional (HCP) to fill out this form. By clicking submit, you are confirming you are a health care professional. Please do not include any patient-identifying information.

Submitting…

Sage Therapeutics

© 2015 SAGE Therapeutics. Terms of Use